Suchergebnisse - "Monoclonal"

Efficacy and Safety of All Monoclonal Antibodies in Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis.

Autoren: Cai W Fu L Wu Y et al.

Quelle: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2025 Dec; Vol. 34 (12), pp. e70268.

Publikationsart: Journal Article; Systematic Review; Meta-Analysis; Review

Info zur Zeitschrift: Publisher: Wiley Country of Publication: England NLM ID: 9208369 Publication Model: Print Cited Medium: Internet ISSN: 1099-1557 (Electronic) Linking ISSN: 10538569 NLM ISO Abbreviation: Pharmacoepidemiol Drug Saf Subsets: MEDLINE

MeSH-Schlagworte: Dermatitis, Atopic*/drug therapy , Antibodies, Monoclonal*/adverse effects , Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/therapeutic use, Humans ; Severity of Illness Index ; Randomized Controlled Trials as Topic ; Network Meta-Analysis as Topic ; Treatment Outcome ; Quality of Life ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/administration & dosage

First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study.

Autoren: Kournoutas I Marell P Gile J et al.

Quelle: The oncologist [Oncologist] 2025 Nov 11; Vol. 30 (11).

Publikationsart: Journal Article; Multicenter Study

Info zur Zeitschrift: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

MeSH-Schlagworte: Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/pharmacology , Antibodies, Monoclonal, Humanized*/administration & dosage , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/mortality , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/mortality , Bevacizumab*/therapeutic use , Bevacizumab*/pharmacology , Bevacizumab*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/pharmacology, Humans ; Male ; Aged ; Female ; Retrospective Studies ; Middle Aged ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal/pharmacology ; Aged, 80 and over

Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed.

Autoren: Mitsikostas DD Awad SF Kongerslev R et al.

Quelle: Advances in therapy [Adv Ther] 2025 Nov; Vol. 42 (11), pp. 5742-5760. Date of Electronic Publication: 2025 Sep 23.

Publikationsart: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III

Info zur Zeitschrift: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE

MeSH-Schlagworte: Migraine Disorders*/prevention & control , Migraine Disorders*/drug therapy , Migraine Disorders*/economics , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/economics , Calcitonin Gene-Related Peptide*/antagonists & inhibitors , Calcitonin Gene-Related Peptide*/immunology , Calcitonin Gene-Related Peptide Receptor Antagonists*/therapeutic use , Calcitonin Gene-Related Peptide Receptor Antagonists*/economics, Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/economics ; Adult ; Double-Blind Method ; Numbers Needed To Treat ; Male ; Female ; Middle Aged ; Randomized Controlled Trials as Topic

Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.

Autoren: Ohama H Hiraoka A Tada T et al.

Körperschaften: Ohama H Hiraoka A Tada T et al.

Quelle: Journal of gastroenterology [J Gastroenterol] 2025 Nov; Vol. 60 (11), pp. 1427-1436. Date of Electronic Publication: 2025 Aug 20.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Springer International Country of Publication: Japan NLM ID: 9430794 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-5922 (Electronic) Linking ISSN: 09441174 NLM ISO Abbreviation: J Gastroenterol Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/immunology , Liver Neoplasms*/drug therapy , Liver Neoplasms*/immunology , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Female ; Aged ; Retrospective Studies ; Risk Factors ; Middle Aged ; Nutrition Assessment ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/administration & dosage ; Geriatric Assessment ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/administration & dosage ; Nutritional Status

Safety, Tolerability, and Pharmacokinetics of the Long-Acting SARS-CoV-2-Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults.

Autoren: Li N Zhang J Zhang W et al.

Quelle: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2025 Nov; Vol. 14 (11), pp. 836-845. Date of Electronic Publication: 2025 Aug 13.

Publikationsart: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I

Info zur Zeitschrift: Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2160-7648 (Electronic) Linking ISSN: 2160763X NLM ISO Abbreviation: Clin Pharmacol Drug Dev Subsets: MEDLINE

MeSH-Schlagworte: Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/pharmacokinetics , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Neutralizing*/administration & dosage , Antibodies, Neutralizing*/adverse effects , Antibodies, Neutralizing*/blood , Antiviral Agents*/adverse effects , Antiviral Agents*/administration & dosage , Antiviral Agents*/pharmacokinetics , COVID-19 Drug Treatment* , SARS-CoV-2*/immunology , SARS-CoV-2*/drug effects, Adult ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; Antibodies, Viral/blood ; China ; COVID-19 ; Double-Blind Method ; Half-Life ; Healthy Volunteers ; Injections, Intramuscular ; East Asian People ; Antibodies, Monoclonal ; Drug Combinations

IL-1 targeting agents in Schnitzler syndrome: a multicentre, real-world study from the international AIDA Network Schnitzler Registry.

Autoren: Calabrese L Cartocci A Vitale A et al.

Quelle: Clinical and experimental rheumatology [Clin Exp Rheumatol] 2025 Oct; Vol. 43 (10), pp. 1753-1762. Date of Electronic Publication: 2025 Oct 23.

Publikationsart: Journal Article; Multicenter Study

Info zur Zeitschrift: Publisher: Clinical And Experimental Rheumatology S.A.S Country of Publication: Italy NLM ID: 8308521 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0392-856X (Print) Linking ISSN: 0392856X NLM ISO Abbreviation: Clin Exp Rheumatol Subsets: MEDLINE

MeSH-Schlagworte: Schnitzler Syndrome*/drug therapy , Schnitzler Syndrome*/immunology , Schnitzler Syndrome*/diagnosis , Interleukin 1 Receptor Antagonist Protein*/therapeutic use , Interleukin 1 Receptor Antagonist Protein*/adverse effects , Interleukin-1*/antagonists & inhibitors , Interleukin-1*/immunology , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/adverse effects , Antirheumatic Agents*/therapeutic use , Antirheumatic Agents*/adverse effects, Humans ; Registries ; Male ; Female ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects ; Treatment Outcome ; Adult ; Time Factors ; Adolescent ; Young Adult ; Middle Aged ; Child ; Child, Preschool ; Remission Induction

The clinical outcome of patients starting monoclonal antibodies anti-CGRP with concomitant migraine preventive treatments.

Autoren: Fofi L Altamura C Marcosano M et al.

Quelle: Cephalalgia : an international journal of headache [Cephalalgia] 2025 Oct; Vol. 45 (10), pp. 3331024251378776. Date of Electronic Publication: 2025 Oct 17.

Publikationsart: Journal Article; Observational Study; Multicenter Study

Info zur Zeitschrift: Publisher: Sage Country of Publication: England NLM ID: 8200710 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2982 (Electronic) Linking ISSN: 03331024 NLM ISO Abbreviation: Cephalalgia Subsets: MEDLINE

MeSH-Schlagworte: Migraine Disorders*/prevention & control , Migraine Disorders*/drug therapy , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage , Calcitonin Gene-Related Peptide*/antagonists & inhibitors , Calcitonin Gene-Related Peptide*/immunology, Humans ; Male ; Female ; Adult ; Middle Aged ; Prospective Studies ; Treatment Outcome ; Cohort Studies ; Antibodies, Monoclonal, Humanized

Exposure during pregnancy to Il-1 targeted therapies and pregnancy, foetal and neonatal outcomes: a study from the French Teratology Information Service.

Autoren: Faure-Bardon V Beghin D Fautrel B et al.

Quelle: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2025 Dec 01; Vol. 64 (12), pp. 6106-6113.

Publikationsart: Journal Article; Observational Study

Info zur Zeitschrift: Publisher: Oxford University Press Country of Publication: England NLM ID: 100883501 Publication Model: Print Cited Medium: Internet ISSN: 1462-0332 (Electronic) Linking ISSN: 14620324 NLM ISO Abbreviation: Rheumatology (Oxford) Subsets: MEDLINE

MeSH-Schlagworte: Interleukin 1 Receptor Antagonist Protein*/adverse effects , Interleukin 1 Receptor Antagonist Protein*/therapeutic use , Antirheumatic Agents*/adverse effects , Antirheumatic Agents*/therapeutic use , Pregnancy Complications*/drug therapy , Abnormalities, Drug-Induced*/epidemiology , Abnormalities, Drug-Induced*/etiology , Antibodies, Monoclonal*/adverse effects , Antibodies, Monoclonal*/therapeutic use , Interleukin-1*/antagonists & inhibitors, Humans ; Pregnancy ; Female ; Antibodies, Monoclonal, Humanized/adverse effects ; France/epidemiology ; Pregnancy Outcome ; Adult ; Retrospective Studies ; Infant, Newborn ; Prospective Studies

Successful treatment of generalized pustular psoriasis during pregnancy with secukinumab in a patient hypersensitive to spesolimab: a case report.

Autoren: Zhang S Peng G Zhang Y et al.

Quelle: The Journal of dermatological treatment [J Dermatolog Treat] 2025 Dec; Vol. 36 (1), pp. 2474495. Date of Electronic Publication: 2025 Mar 20.

Publikationsart: Journal Article; Case Reports

Info zur Zeitschrift: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE

MeSH-Schlagworte: Psoriasis*/drug therapy , Psoriasis*/diagnosis , Psoriasis*/pathology , Pregnancy Complications*/drug therapy , Dermatologic Agents*/administration & dosage , Dermatologic Agents*/therapeutic use , Dermatologic Agents*/adverse effects , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/adverse effects, Humans ; Female ; Pregnancy ; Adult ; Antibodies, Monoclonal, Humanized ; Treatment Outcome

Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review.

Autoren: Yang HJ Spratt W Lai FYX et al.

Quelle: The Journal of dermatological treatment [J Dermatolog Treat] 2025 Dec; Vol. 36 (1), pp. 2495834. Date of Electronic Publication: 2025 Apr 29.

Publikationsart: Journal Article; Case Reports; Review

Info zur Zeitschrift: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE

MeSH-Schlagworte: Pyoderma Gangrenosum*/drug therapy , Pyoderma Gangrenosum*/diagnosis , Pseudomonas Infections* , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/adverse effects, Humans ; Male ; Middle Aged ; Antibodies, Monoclonal, Humanized ; Adult ; Female ; Treatment Outcome ; Recurrence

Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma.

Autoren: Chow RD Mamtani R

Quelle: Clinical genitourinary cancer [Clin Genitourin Cancer] 2025 Dec; Vol. 23 (6), pp. 102417. Date of Electronic Publication: 2025 Aug 17.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE

MeSH-Schlagworte: Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Weight Loss*/drug effects , Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/mortality , Carcinoma, Transitional Cell*/pathology , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/mortality , Urinary Bladder Neoplasms*/pathology, Humans ; Male ; Female ; Retrospective Studies ; Aged ; Middle Aged ; Antibodies, Monoclonal/administration & dosage ; Aged, 80 and over ; Prognosis ; Progression-Free Survival

Remarkable response to durvalumab and tremelimumab in a patient with hepatocellular carcinoma: a case report.

Autoren: Osawa Y Akita T Igarashi Y et al.

Quelle: Clinical journal of gastroenterology [Clin J Gastroenterol] 2025 Dec; Vol. 18 (6), pp. 1144-1148. Date of Electronic Publication: 2025 Sep 26.

Publikationsart: Journal Article; Case Reports

Info zur Zeitschrift: Publisher: Springer Japan Country of Publication: Japan NLM ID: 101477246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-7265 (Electronic) Linking ISSN: 18657265 NLM ISO Abbreviation: Clin J Gastroenterol Subsets: MEDLINE

MeSH-Schlagworte: Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Male ; Middle Aged ; B7-1 Antigen/metabolism ; Aged ; Female ; Bevacizumab

Anti-amyloid monoclonal antibody therapies in Alzheimer's disease - a scoping review.

Autoren: Elamin SA Al Shibli AN Shaito A et al.

Quelle: Neuroscience [Neuroscience] 2025 Nov 28; Vol. 589, pp. 50-61. Date of Electronic Publication: 2025 Oct 10.

Publikationsart: Journal Article; Scoping Review; Review

Info zur Zeitschrift: Publisher: Elsevier Science Country of Publication: United States NLM ID: 7605074 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7544 (Electronic) Linking ISSN: 03064522 NLM ISO Abbreviation: Neuroscience Subsets: MEDLINE

MeSH-Schlagworte: Alzheimer Disease*/drug therapy , Amyloid beta-Peptides*/immunology , Amyloid beta-Peptides*/antagonists & inhibitors , Amyloid beta-Peptides*/metabolism , Antibodies, Monoclonal*/therapeutic use, Humans ; Antibodies, Monoclonal, Humanized/therapeutic use

Efficacy of alternative vs. standard dosing strategies of anti-CD20 monoclonal antibodies in multiple sclerosis: A systematic review and meta-analysis.

Autoren: Mohammadi I Rajai Firouzabadi S Aghajanian S et al.

Quelle: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2025 Nov; Vol. 103, pp. 106668. Date of Electronic Publication: 2025 Aug 08.

Publikationsart: Journal Article; Systematic Review; Meta-Analysis; Review

Info zur Zeitschrift: Publisher: Elsevier B. V Country of Publication: Netherlands NLM ID: 101580247 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-0356 (Electronic) Linking ISSN: 22110348 NLM ISO Abbreviation: Mult Scler Relat Disord Subsets: MEDLINE

MeSH-Schlagworte: Multiple Sclerosis*/drug therapy , Antigens, CD20*/immunology , Immunologic Factors*/administration & dosage , Antibodies, Monoclonal*/administration & dosage , Rituximab*/administration & dosage, Humans ; Antibodies, Monoclonal, Humanized/administration & dosage

[Use of IL-1 inhibitors in the treatment of familial Mediterranean fever in pediatric rheumatology].

Transliterierter Titel: Il-1-Inhibitoren zum Management des familiären Mittelmeerfiebers in der Kinderrheumatologie.

Autoren: Hillekamp C Wahl J Zimmer A et al.

Quelle: Zeitschrift fur Rheumatologie [Z Rheumatol] 2025 Nov; Vol. 84 (9), pp. 694-702. Date of Electronic Publication: 2025 Aug 19.

Publikationsart: English Abstract; Journal Article

Info zur Zeitschrift: Publisher: Springer Country of Publication: Germany NLM ID: 0414162 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-1250 (Electronic) Linking ISSN: 03401855 NLM ISO Abbreviation: Z Rheumatol Subsets: MEDLINE

MeSH-Schlagworte: Familial Mediterranean Fever*/drug therapy , Familial Mediterranean Fever*/diagnosis , Familial Mediterranean Fever*/genetics , Interleukin 1 Receptor Antagonist Protein*/administration & dosage , Interleukin 1 Receptor Antagonist Protein*/therapeutic use , Interleukin-1*/antagonists & inhibitors , Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/therapeutic use, Humans ; Male ; Child ; Female ; Treatment Outcome ; Antibodies, Monoclonal, Humanized ; Adolescent ; Antirheumatic Agents/administration & dosage ; Child, Preschool ; Colchicine/administration & dosage ; Colchicine/therapeutic use ; Germany/epidemiology ; Pyrin/genetics

Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.

Autoren: Zenke Y Shiraishi Y Goto Y et al.

Quelle: Cancer science [Cancer Sci] 2025 Nov; Vol. 116 (11), pp. 3171-3184. Date of Electronic Publication: 2025 Sep 21.

Publikationsart: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study

Info zur Zeitschrift: Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE

MeSH-Schlagworte: Small Cell Lung Carcinoma*/therapy , Small Cell Lung Carcinoma*/drug therapy , Small Cell Lung Carcinoma*/pathology , Small Cell Lung Carcinoma*/mortality , Lung Neoplasms*/therapy , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/mortality , Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/adverse effects , Antibodies, Monoclonal*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Aged ; Chemoradiotherapy/methods ; Adult ; Japan ; Antibodies, Monoclonal, Humanized/administration & dosage ; Double-Blind Method ; Progression-Free Survival ; Etoposide/administration & dosage ; Cisplatin/administration & dosage ; Aged, 80 and over ; Carboplatin/administration & dosage ; East Asian People

Coronavirus Disease 2019 (COVID-19) in Heart Transplant Recipients and Anti-SARS-CoV-2 Monoclonal Antibodies: Experience, Lessons Learnt, and Future Challenges.

Autoren: Kapur R Okumura K Ohira S et al.

Quelle: Cardiology in review [Cardiol Rev] 2025 Nov-Dec 01; Vol. 33 (6), pp. 522-530. Date of Electronic Publication: 2024 Feb 08.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9304686 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-4683 (Electronic) Linking ISSN: 10615377 NLM ISO Abbreviation: Cardiol Rev Subsets: MEDLINE

MeSH-Schlagworte: Heart Transplantation* , COVID-19*/prevention & control , COVID-19*/epidemiology , COVID-19 Drug Treatment* , Antibodies, Monoclonal*/therapeutic use, Humans ; SARS-CoV-2 ; Antibodies, Monoclonal, Humanized/therapeutic use ; Male ; Middle Aged ; Retrospective Studies ; Female ; Adult ; Aged ; Transplant Recipients ; Drug Combinations ; Antibodies, Neutralizing

Combination therapy of ofatumumab and daratumumab in patients with severe anti-NMDA receptor encephalitis.

Autoren: Wang B Chu Y Zhang C et al.

Quelle: Frontiers in immunology [Front Immunol] 2025 Oct 27; Vol. 16, pp. 1681884. Date of Electronic Publication: 2025 Oct 27 (Print Publication: 2025).

Publikationsart: Journal Article; Case Reports

Info zur Zeitschrift: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

MeSH-Schlagworte: Anti-N-Methyl-D-Aspartate Receptor Encephalitis*/drug therapy , Anti-N-Methyl-D-Aspartate Receptor Encephalitis*/diagnosis , Anti-N-Methyl-D-Aspartate Receptor Encephalitis*/immunology , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage, Humans ; Female ; Adolescent ; Drug Therapy, Combination ; Treatment Outcome ; Antibodies, Monoclonal, Humanized

Low-dose emapalumab treatment in refractory macrophage activation syndrome secondary to adult onset still's disease/systemic lupus erythematosus: insights from nine cases.

Autoren: Chen J Zhao L Lin Y et al.

Quelle: Frontiers in immunology [Front Immunol] 2025 Oct 14; Vol. 16, pp. 1676749. Date of Electronic Publication: 2025 Oct 14 (Print Publication: 2025).

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

MeSH-Schlagworte: Macrophage Activation Syndrome*/drug therapy , Macrophage Activation Syndrome*/etiology , Lupus Erythematosus, Systemic*/complications , Lupus Erythematosus, Systemic*/drug therapy , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Still's Disease, Adult-Onset*/complications , Still's Disease, Adult-Onset*/drug therapy, Humans ; Female ; Adult ; Male ; Middle Aged ; Treatment Outcome ; Young Adult ; Antibodies, Monoclonal ; Antibodies, Neutralizing

A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19.

Autoren: Edge R Matthews S Ahani B et al.

Quelle: Nature communications [Nat Commun] 2025 Oct 14; Vol. 16 (1), pp. 9101. Date of Electronic Publication: 2025 Oct 14.

Publikationsart: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

Info zur Zeitschrift: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

MeSH-Schlagworte: Antibodies, Monoclonal*/immunology , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage , Antibodies, Viral*/immunology , Antibodies, Viral*/blood , COVID-19*/prevention & control , COVID-19*/immunology , COVID-19*/virology , Pre-Exposure Prophylaxis*/methods , SARS-CoV-2*/immunology , SARS-CoV-2*/genetics , SARS-CoV-2*/drug effects, Female ; Humans ; Male ; Middle Aged ; Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/blood ; COVID-19 Drug Treatment ; Proportional Hazards Models

SCR Organism: SARS-CoV-2 variants